Moderna, Inc. (MRNA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは Stéphane Bancel.
MRNA を有する IPO日 2018-12-07, 5,800 名の正社員, に上場 NASDAQ Global Select, 時価総額 $20.87B.
Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. The company's portfolio spans multiple therapeutic areas including infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases, with products marketed across the United States, Europe, and internationally. Moderna's vaccine pipeline includes respiratory vaccines such as COVID-19 and influenza, latent vaccines targeting viral infections like HIV and cytomegalovirus, and cancer vaccines including personalized and KRAS-directed therapies. The company maintains strategic partnerships with leading pharmaceutical and biotech firms including Merck, AstraZeneca, Vertex Pharmaceuticals, and collaborates with governmental and philanthropic organizations such as BARDA and The Bill & Melinda Gates Foundation. Founded in 2010 and rebranded as Moderna, Inc. in 2018, the company continues to advance mRNA-based solutions across multiple disease areas.
